Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: determined (252), resolute (3)

Carboplatin(AUC2)-Paclitaxel RT

Description: Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CARBOPLATIN (AUC2)-PACLITAXEL-RADIOTHERAPY Regimen • Gastrointestinal (Upper) Cancer
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/CarboplatinAUC2-Paclitaxel-RT.pdf

Bevacizumab-Irinotecan Ver 1.1

Description: Chemotherapy Protocol COLORECTAL CANCER BEVACIZUMAB-IRINOTECAN This protocol may require funding Regimen Colorectal Cancer – B
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Bevacizumab-IrinotecanVer11.pdf

Anastrozole-Ribociclib

Description: Chemotherapy Protocol Breast Cancer Anastrozole-Ribociclib Regimen • Breast Cancer – Anastrozole-Ribociclib Indication • Ribociclib in combination with an aromatase inhibitor is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Anastrozole-Ribociclib.pdf

NHS medical director tours COVID testing facilities at UHS

Description: NHS England medical director Professor Stephen Powis met with staff at UHS earlier today (Friday) to find out more about the
Url: /AboutTheTrust/Newsandpublications/Latestnews/2020/October/NHS-medical-director-tours-COVID-testing-facilities-at-UHS.aspx

UHS power failure incident - additional information

Description: Further to the public statements issued yesterday (Wednesday) concerning a major incident at University Hospital Southampton NHS Foundation Trust, we have
Url: /AboutTheTrust/Newsandpublications/Latestnews/2018/November-2018/UHS-power-failure-incident-additional-information.aspx

Docetaxel-Pertuzumab-Trastuzumab Ver 1.3

Description: Chemotherapy Protocol BREAST CANCER DOCETAXEL-PERTUZUMAB-TRASTUZUMAB This protocol may require funding Re
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Docetaxel-Pertuzumab-Trastuzumab.pdf

Bevacizumab (7.5mgkg), Carboplatin(AUC5) and Paclitaxel (21 day)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (7.5)-CARBOPLATIN (AUC5)-PACLITAXEL (21 day) Regimen • Ovary-Bevacizum
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab7.5mgkgCarboplatinandPaclitaxel21day.pdf

Annual complaints report 2020-21

Description: ANNUAL COMPLAINTS REPORT 2020/21 RETROSPECTIVE PERFORMANCE LOOKING FORWARDS “All patients, from every background and walk of life, will experience the
Url: /Media/UHS-website-2019/Patientinformation/Contactingus/Annual-complaints-report-2020-21.pdf

Ipilimumab-Nivolumab

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/kg)-Nivolumab (1mg/kg) Indication • Ipilimumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf

Ipilimumab-Nivolumab Ver1

Description: Chemotherapy Protocol MESOTHELIOMA IPILIMUMAB-NIVOLUMAB Regimen • Mesothelioma – Ipilimumab-Nivolumab Indication • Nivolumab in combination with ipilimumab is indicated for the first-line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/Ipilimumab-Nivolumab-Ver1.pdf

251 to 260 of 496

Previous … 24 25 26 27 28 … Next